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Abstract
Hypothesis: Serum- and Glucocorticoid-inducible Kinase 1 (SGK1) is involved in the regulation of insulin secretion and may
represent a candidate gene for the development of type 2 diabetes mellitus in humans.
Methods: Three independent European populations were analyzed for the association of SGK1 gene (SGK) variations and
insulin secretion traits. The German TUEF project provided the screening population (N=725), and four tagging SNPs
(rs1763527, rs1743966, rs1057293, rs9402571) were investigated. EUGENE2 (N=827) served as a replication cohort for the
detected associations. Finally, the detected associations were validated in the METSIM study, providing 3798 non-diabetic
and 659 diabetic (type 2) individuals.
Results: Carriers of the minor G allele in rs9402571 had significantly higher C-peptide levels in the 2 h OGTT (+10.8%,
p=0.04; dominant model) and higher AUCC-Peptide/AUCGlc ratios (+7.5%, p=0.04) compared to homozygous wild type TT
carriers in the screening population. As interaction analysis for BMI6rs9402571 was significant (p=0.04) for the endpoint
insulin secretion, we stratified the TUEF cohort for BMI, using a cut off point of BMI=25. The effect on insulin secretion only
remained significant in lean TUEF participants (BMI#25). This finding was replicated in lean EUGENE2 rs9402571 minor allele
carriers, who had a significantly higher AUCIns/AUCGlc (TT: 22667, XG: 24669; p=0.019). Accordingly, the METSIM trial
revealed a lower prevalence of type 2 diabetes (OR: 0.85; 95%CI: 0.71–1.01; p=0.065, dominant model) in rs9402571 minor
allele carriers.
Conclusions: The rs9402571 SGK genotype associates with increased insulin secretion in lean non-diabetic TUEF/EUGENE2
participants and with lower diabetes prevalence in METSIM. Our study in three independent European populations supports
the conclusion that SGK variability affects diabetes risk.
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Introduction
Type 2 diabetes arises when insulin resistance cannot be
compensated for with increased insulin secretion owing to a
gradual loss of pancreatic beta-cell function [1]. Recently,
genome-wide association studies have been undertaken to further
investigate the genetic background of type 2 diabetes, revealing
that many high risk alleles are located within genes that are linked
to beta cell function, including TCF7L2 [2,3,4], CDKAL1
[5,6,7,8], SLC30A8 [5,9,10], IGF2BP2 [5], HHEX/IDE
[6,9,11,12], and CDKN2A/B [13]. Our study therefore focuses
on genes that play a role in insulin secretion, using a classical
candidate-gene approach.
One interesting candidate for the regulation of insulin secretory
function is the serum and glucocorticoid inducible kinase SGK1,
which is a ubiquitously expressed serine-threonine kinase in
PLoS ONE | www.plosone.org 1 November 2008 | Volume 3 | Issue 11 | e3506humans that is encoded by the gene SGK on chromosome 6q23.
SGK1 was originally identified in rodents as a serum and
glucocorticoid regulated kinase [14], and was shown to be up-
regulated by mineralocorticoids [15], TGF-ß1, and insulin [16].
SGK1 seems to provide an important molecular link between salt
and glucose homeostasis, as SGK1
2/2 knockout mice fed with
high-salted chow demonstrated decreased SGK1-dependent
cellular glucose uptake [17]. Beyond SGK1 functions in
transmembranous glucose transport [18,19,20,21] and insulin
signalling [16], SGK1 also plays a role in insulin secretion. In INS-
1 cells, SGK gene transcription and protein expression is strongly
regulated, and SGK1 up-regulates the activity of voltage-gated K
+
channels, which in turn reduces Ca
++ influx and inhibits insulin
release [22]. Another SGK1-dependent molecular mechanism in
insulin secretion is the activation of Na
+/K
+-ATPase during
plasma membrane repolarisation [23].
Taken together, compelling evidence points to a role of this
ubiquitously expressed serine/threonine kinase SGK1 in glucose
metabolism, especially in the regulation of insulin secretion. So far,
studies on the role of SGK genetic variance in human physiology
are rather limited. Two studies confirmed an association of SGK
variability with blood pressure in a German twin population [24]
and the cohort of the Scandinavian Malmo Diet and Cancer
Study [25]. We conducted our study on SGK genetic variance and
potential associations with insulin secretory function in the
German TUEF cohort and the EUGENE2 consortium (Denmark,
Finland, Germany, Italy, and Sweden), as these two European
diabetes risk populations were extensively phenotyped for insulin
secretion traits at the prediabetic stage. To confirm the relevance
of associations found for later onset of type 2 diabetes mellitus,
corresponding SGK risk alleles were further investigated in the
METSIM Trial, which provides a large population-based Finnish
cohort for the endpoint diabetes. Analyzing four selected tagging
SNPs of SGK, the SNP rs9402571 was consistently found to be
associated with altered insulin secretion in both prediabetic
populations, and was further confirmed to associate with the
prevalence of type 2 diabetes mellitus in the population-based
cohort.
Methods
Participants
Three independent European cohorts were analyzed for SGK
genetic variance and insulin secretion traits for this study. The
TUEF project provided the screening population, while EU-
GENE2 served as a replication cohort for insulin secretion traits.
METSIM is a population-based cohort providing both non-
diabetic and type 2 diabetic individuals, and was employed for
estimation of SGK diabetes-risk alleles. Further details on each of
the three study cohorts are provided in the following, with baseline
characteristics presented in Table 1.
TUEF cohort. The TUEF (Tuebingen Familiy Study) cohort
includes non-diabetic individuals from southern Germany with
increased risks for developing type 2 diabetes (family history of
type 2 diabetes, diagnosis of impaired fasting glucose). The study
protocol included standard procedures as medical history, physical
examination, routine blood tests and oral glucose tolerance test
with blood sampling (plasma insulin, plasma glucose, plasma C-
peptide) at 0, 30, 60, 90 and 120 min [26]. Informed written
consent was obtained from all participants, and all study
procedures were approved by the local medical ethic research
committee of the Faculty of Medicine at the University of
Tuebingen. 1000 TUEF participants were genotyped for SGK and
phenotyped by OGTT and AUCCP/AUCGlc (see below). For
further investigation, individuals with one of the following criteria
were excluded: taking medications known to affect glucose
tolerance, severe diseases (malignancies, cardiovascular or
psychiatric disease, etc.), newly diagnosed diabetes, positive
GAD antibodies, and one or more missing parameters needed
for AUCCP/AUCGlc calculation. This method of elimination
resulted in a final study cohort of 725 non-diabetic individuals.
EUGENE2 consortium. Five different European clinical
diabetes centres contributed non-diabetic offspring of patients
with type 2 diabetes to the EUGENE2 (European network on
Functional Genomics of Type 2 Diabetes) consortium, including
the Lundberg Laboratory for Diabetes Research (Go ¨teborg,
Sweden), the Polyclinic Mater Domini of the University Magna
Graecia (Catanzaro, Italy), the Steno Diabetes Center
(Copenhagen, Denmark), the Kuopio University Hospital
(Kuopio, Finland), and the Tu ¨bingen University Hospital
(Tu ¨bingen, Germany). All study participants underwent a
standard medical history, routine laboratory testing, assessment
of social issues (alcohol consumption, activity, smoking status), and
an OGTT. Informed written consent was obtained of all
participants, and the local ethics committees approved the study
protocol at the different centres. Further details about the
EUGENE2 consortium are provided elsewhere [27].
METSIM cohort. The Finnish cohort comprised 4457 male
participants, aged from 50 to 70 years. Among them, 43.4% had a
family history of diabetes. The primary aim of the ongoing
METSIM (METabolic Syndrome In Men) trial is to investigate
the effects of SNPs in genes of interest on the risk of type 2 diabetes
and cardiovascular disease in a random sample of Finnish men,
living in the town of Kuopio (population 95,000), in eastern
Finland [4]. The WHO criteria in 1999 for diabetes mellitus were
used for classification of the METSIM participants, based on
fasting plasma glucose and 2-hour post-load glucose levels in an
OGTT [28] conducted at baseline. Among the 4457 participants,
659 had known or newly diagnosed diabetes and 3798 were non-
diabetic. The protocol includes a 1-day visit to the Clinical
Research Unit of the University of Kuopio. This study was
approved by the Ethics Committee of the University of Kuopio
and was in accordance with the Helsinki Declaration.
Body composition and body fat distribution
Body mass index (BMI) was calculated as weight divided by the
square of height (kg/m
2). Waist and hip circumferences were
measured in the upright position.
Table 1. Characteristics of the 3 investigated study
populations.
TUEF
a EUGENE2
b METSIM
c
(N=725) (N=827) (N=4457)
Gender (m/f) 261/464 344/483 4457/-
Age (years) 37.2612.5 40.1610.3 59,565.9
BMI 29.368.8 26.665.0 27,464.2
Waist (cm) 93.9618.4 89.0613.4 99,1611.5
Data are presented as means6SD.
aTuebingen Family Study (South Germany; non-diabetic individuals).
bFinns, Danish, Dutch, Swedish and Germans from the EUGENE2 consortium
[27]. Only non-diabetic EUGENE2 participants with complete datasets for
AUCIns/AUCGluc calculations were analyzed.
cMETabolic Syndrome In Men (METSIM) cohort from Kuopio (Finland),
population-based (non-diabetic and diabetic individuals).
doi:10.1371/journal.pone.0003506.t001
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Blood glucose was determined using a bedside glucose analyzer
(Yellow Springs Instruments, Yellow Springs, CO, USA). Plasma
insulin was determined by microparticle enzyme immunoassay
(Abbott Laboratories, Tokyo, Japan) for both the TUEF and
EUGENE2 cohorts. Plasma C-peptide was determined by
radioimmunoassay (Byk-Sangtec, Dietzen bach, Germany).
Oral glucose tolerance test (OGTT)
The OGTT was performed according to the recommendations
of the World Health Organization after a 12 h fasting period [28].
Blood glucose, insulin (all centres), and C-peptide (TUEF cohort
only) plasma levels were determined at 0, 30, 60, 90, and 120 min.
Insulin sensitivity and insulin secretion
Insulin sensitivity was calculated from glucose and insulin values
obtained during the OGTT, as proposed by Matsuda and
DeFronzo [29]. Estimation of insulin secretion by the OGTT
parameters was obtained by C-peptide levels measured at 30 min
during the OGTT. Alternatively, insulin secretory function was
calculated by the ratio of the area under the curve (AUC) of C-
peptide (AUCCP; TUEF cohort) or insulin (AUCIns; EUGENE2
cohort) plasma levels, referred to as the AUC of plasma glucose
(AUCGlc), using the trapezoidal approximation rule for AUC
calculation [30].
SNP Genotyping
The SGK (NM_005627) gene on chromosome 6q23 was
subjected to Hap Map analysis in the CEU population (Utah
residents with ancestry from Northern and Western Europe; data
release 21a/Jan07). Tagging SNPs were selected using the
TagSNP Picker software (settings: multimarker mode
MAF.0.05, r
2.0.9), screening the complete SGK gene, 10 kb of
the promoter, and 1.5 kb downstream of the 39 untranslated
region. Genotyping of tagging SNPs was accomplished by means
of the TaqManH assay and an ABI Prism 7500 sequence detection
system (Applied Biosystems, Foster City, CA, USA). Genotyping
quality was tested by including three known controls of each
genotype in each assay.
Data Analysis
Unless otherwise noted, data are stated as means6SEM.
Comparison between genotype groups was performed using
logarithmically transformed data for non-normally distributed
parameters in ANOVA and t-tests. Each effect was adjusted for
relevant covariates using mixed linear models. Parameters that
remained non-normally distributed despite log transformation
were directly analyzed by a non-parametric (Wilcoxon) test.
Association with diabetes (METSIM) was tested using logistic
regression analysis. Hardy-Weinberg equilibrium was tested with
the x
2 test. A p-value#0.05 was considered to be statistically
significant. The software package JMP (SAS Institute Inc, Cary,
NC, USA) and SPSS 14.0 for Windows (SPSS Inc., Chicago, IL,
USA) were used for statistical data analysis. The software JLIN
(Western Australian Institute for Medical Research) was used for
calculation of linkage disequilibrium [31].
Results
Genetic analysis of the human SGK gene
The human SGK gene comprises 12 exons spanning 5.6 kb on
chr6q23. Analysis of a 17 kb region of the SGK locus by Tag SNP
Picker revealed five tagSNPs in the HapMap, each with a minor
allele frequency (MAF) of .0.05 in the CEU population. Four
SNPs (rs1763527, rs1743966, rs1057293, and rs9402571) were
finally selected for genotyping, covering 83% of all SNPs fulfilling
the inclusion criteria mentioned above. Both rs1743966 (intron 6)
and rs1057293 (exon 8; synonymous: Asp/Asp) are located within
the SGK gene, while rs1763527 (promoter) and rs9402571
(1429 bp downstream of the SGK 39UTR) tag the regions
surrounding SGK. MAF and Hardy-Weinberg-Equilibrium test
results of all tagging SNPs are indicated for the TUEF and
EUGENE2 cohort in Fig. 1A, with linkage disequilibrium (LD)
analysis provided in Fig. 1B.
SGK association analyses in the TUEF screening cohort
There was no association between genotypes, anthropometrics,
and insulin sensitivity in the south German screening cohort,
which was investigated for all four tagging SNPs (data not shown).
Most consistently, two different indices of insulin secretion differed
significantly among rs9402571 genotypes (Table 2). Minor allele
carriers of rs9402571 had significantly higher C-Peptide levels in
the 2 h OGTT than individuals with the wild type allele (+10.8%,
p=0.04, dominant model), after adjustment for age, gender, BMI,
and insulin sensitivity. This genotype also associated with better
AUCC-Peptide/AUCGlc ratios (+7.5%, p=0.04; dominant model,
adjusted for age, BMI and gender; Table 2).
Interaction analysis and replication in EUGENE2
An interaction analysis for the trait of insulin secretion was
performed. BMI6rs9402571 genotype was revealed to be
significantly relevant for the endpoint insulin secretion in TUEF,
independent of which calculation model for insulin secretion was
used (p=0.04, both models) and of whether BMI was treated as a
continuous or discrete variable with BMI cut-off points ranging
from 24 to 28 kg/m
2. We therefore stratified the cohort for BMI,
using a cut off point of BMI=25 to distinguish lean from
overweight or obese individuals, and did a reanalysis for insulin
secretion for both subgroups. The effect on AUCCP/AUCGlc was
only significant in the lean TUEF subgroup (BMI#25: TT:
31865, TG: 33567, GG: 342617; p=0.031; dominant model,
adjusted for age, gender, and insulin sensitivity; Fig. 2A), while
there was no association with insulin secretory function in
overweight to obese study participants (BMI.25; p.0.24, all;
additive and dominant models; data not shown). To replicate our
findings of the association between rs9402571 and insulin
secretion, the EUGENE2 cohort was genotyped for rs9402571
and the AUCIns/AUCGlc ratio was calculated for each genotype.
Again, AUCIns/AUCGlc was significantly higher (TT: 22667, TG:
23969, GG: 289633; p =0.019 for the dominant model; adjusted
for study centre, familial relationship, age, gender, and insulin
sensitivity; Fig. 2B) in lean (BMI#25) minor allele carriers of
rs9402571, while there was no significant association in overweight
to obese individuals (BMI.25: p.0.44; data not shown).
Diabetes risk analysis in the METSIM population-based
cohort
The METSIM cohort was genotyped for all four selected
tagging SNPs to analyze SGK genetic variance for the endpoint
diabetes (type 2) in a population-based cohort. The minor allele of
rs9402571, which was found to associate with a higher insulin
secretion in the screening (TUEF) as well as the replication
(EUGENE2) populations, associated almost significantly
(p=0.065; adjusted for age, family history of diabetes, and BMI)
with a lower prevalence of type 2 diabetes (odds ratio: 0.845;
95%CI: 0.706–1.011), comparing the 659 diabetic patients with
SGK and Insulin Secretion
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was no significantly altered odds ratio in regard to the three other
genotyped SGK tagging SNPs rs1763527, rs1743966, and
rs1057293 (Fig. 3).
Discussion
This is the first study to investigate the role of SGK (Serum- and
Glucocorticoid-inducible Kinase 1) genetic variance in two
independent prediabetic diabetes risk populations (TUEF and
EUGENE2), including a confirmatory analysis in a third
independent, older population that includes both diabetic and
non-diabetic individuals (METSIM). SGK is an attractive candi-
date gene for type 2 diabetes mellitus onset in humans, as SGK1
exerts pleiotropic effects on glucose metabolism and insulin
secretion in various cellular and animal models [16,22,23].
In the screening population (TUEF; N=725), we found a
significant association of rs9402571 with glucose-induced insulin
secretion in various estimation models based on oral glucose
tolerance testing. This association was reproducible in a subgroup
that was additionally phenotyped by an intravenous glucose
tolerance test (data not shown). After confirming a significant
interaction between BMI and rs9402571 for the endpoint insulin
secretion, BMI stratification (BMI cut off: 25) was introduced in
Table 2. Metabolic Traits of the German Cohort according to rs9402571 genotype.
SNP Genotype ______rs9402571______ p1 p2
TT TG GG
N 434 251 40 - -
Age (y) 37.060.6 37.160.8 39.662.2 0.44 0.62
BMI (kg/m
2) 29.060.4 30.060.6 28.961.3 0.24
a 0.20
Fasting glucose (mM) 5.1060.03 5.0560.04 5.0860.09 0.10
b 0.0376
Glucose, 120 min OGTT (mM) 6.1960.08 6.1160.11 6.3360.29 0.31
b 0.16
Insulin sensitivity, OGTT (U) 17.160.5 16.960.8 14.161.4 0.12
b 0.64
C-Peptide, 30 min OGTT (pM) 2020643 2153660 22396158 0.12
c 0.0398
AUCC-peptide/AUCglucose, OGTT (?10
29)3 1 8 653 3 5 673 4 2 618 0.09
b 0.0416
Data are given as means6SEM; p1–additive model; p2–dominant model. AUC–area under the curve; OGTT–oral glucose tolerance test; SNP–single nucleotide
polymorphism.
aadjusted for age and gender.
badjusted for age, gender and BMI.
cadjusted for age, gender, BMI and insulin sensitivity.
doi:10.1371/journal.pone.0003506.t002
Figure 1. The gene encoding human serum- and glucocorticoid-regulated kinase 1 (SGK) on chromosome 6q23. A) Exons (light grey)
and untranslated regions (dark grey) are indicated. Four tagging SNPs were selected by HapMap analysis considering the SGK gene 610 kb upstream
of the first translational start codon and 1.5 kb downstream of the 39 untranslated region. SNP information is provided in boxes (var=variation;
MAF=minor allele frequency; HWE=Hardy-Weinberg equilibrium, x
2 test) for populations investigated for all tagging SNPs (South German TUEF
cohort/Finnish METSIM cohort). B) Linkage disequilibrium analysis of selected tagging SNPs for the TUEF and METSIM population: D’ (in bold, upper
numeral) and r
2 (bottom numeral).
doi:10.1371/journal.pone.0003506.g001
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the rs9402571 minor allele. This genotype-phenotype association
was also restricted to lean individuals in the replication cohort
from the EUGENE2 consortium (N=827), comprising individuals
from Sweden, Italy, Denmark, Finland, and Germany. Interest-
ingly, the rs9402571 allele that associates with higher insulin
secretion in TUEF and EUGENE2 accordingly associates with
lower diabetes prevalence in the METSIM trial. Despite the fact
that SGK1 has a regulatory function for glucose transporter
expression and translocation [18,20,21], no association of the four
investigated SGK tagging SNPs with insulin sensitivity was found in
the TUEF screening population or in the EUGENE2 study. One
could suggest that the SGK rs9402571 SNP was not detected in the
genome-wide association (GWA) studies due to its dependence on
BMI, as the GWA analyses did not stratify for BMI. Interestingly,
a genome-wide linkage analysis identified the gene locus 6q23,
which also includes SGK, to be associated with BMI progression in
participants of the Framingham Heart Study [32].
The increase in insulin secretion reported here (10.8% in
TUEF; 8.8% in EUGENE2) within lean rs9402571 G allele
carriers was remarkable compared to wild type genotype, and may
indicate a protective genotype against type 2 diabetes. This
protective rs9402571 SGK genotype may become blurred in
overweight or obese individuals, as environmental factors may
dominate compared to the SGK genotype. However, our analysis
in the METSIM trial assumed that the protective rs9402571 SGK
genotype effect obviously persists even in a population-based
cohort containing individuals 20 years older than those from the
TUEF and EUGENE2 studies. Therefore, although the number
of study participants was limited after BMI stratification in both
TUEF and EUGENE2, our findings in three independent
European populations allow the assumption that the SGK
rs9402571 genotype is protective against type 2 diabetes. Further
studies on the role of SGK1 in human insulin secretion and
diabetes onset are therefore needed.
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